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OBJECTIVE: Nitric oxide is produced by endothelial nitric oxide synthase, and its production can be influenced
by polymorphisms of the endothelial nitric oxide synthase gene. Because candidate genes responsible for
susceptibility to ankylosing spondylitis are mostly unknown and available data suggest that there may be
problems related to the nitric oxide pathway, such as endothelial dysfunction and increased asymmetric
dimethylarginine, this study aimed to assess the association of common endothelial nitric oxide synthase gene
polymorphisms with ankylosing spondylitis.
METHODS: One hundred ninety-four unrelated Turkish ankylosing spondylitis patients and 113 healthy without
apparent cardiovascular disease, hypertension or diabetes mellitus were included. All individuals were
genotyped by PCR-RFLP for two single-nucleotide polymorphisms, namely 786T.C (rs2070744, promoter
region) and 786 Glu298Asp (rs1799983, exon 7). Variable numbers of tandem repeat polymorphisms in intron 4
were also studied and investigated by direct electrophoresis on agarose gel following polymerase chain
reaction analysis. The Bath ankylosing spondylitis metrology index of the patients was calculated, and human
leukocyte antigen B27 was studied.
RESULTS: All studied polymorphisms satisfied Hardy-Weinberg equilibrium. Sex distributions were similar
between the patient and control groups. No significant differences were found in the distributions of allele and
genotype frequencies of the studied endothelial nitric oxide synthase polymorphisms between patients and
controls. There were no correlations between endothelial nitric oxide synthase polymorphisms, disease
duration, Bath ankylosing spondylitis metrology index or human leukocyte antigen B27.
CONCLUSION: The results presented in this study do not support a major role of common endothelial nitric
oxide synthase polymorphisms in Turkish ankylosing spondylitis patients.
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& INTRODUCTION
Ankylosing spondylitis (AS) is a chronic inflammatory
disease of the spine and sacroiliac joints. Although the
pathogenesis of AS is not known, genetic factors play an
important role in determining susceptibility and disease
severity. HLA–B27 is the major gene associated with AS.
Several non-MHC genes have also been linked to the disease
(1). In recent years, there has been considerable interest
regarding early atherosclerosis and AS (2-4). In this respect,
several studies have suggested an increased prevalence of
endothelial dysfunction, an early step in the pathogenesis of
atherosclerosis (2,3,5,6), in AS. It is well-known that nitric
oxide (NO) is essential in the maintenance of vascular tonus
(7) and that the presence of endothelial impairment (reduced
vascular relaxation) may suggest a problem regarding the
NO pathway. In addition, a considerable number of studies
have reported that asymmetric dimethylarginine (ADMA),
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an endogenous NO inhibitor, is significantly increased in the
blood of AS patients (8-10). Both endothelial impairment and
increased ADMA concentrations suggest the possibility of a
problem related to the NO pathway in AS. NO is produced
by endothelial NO synthase (eNOS), and its production can
be influenced by polymorphisms of the eNOS gene (7).
Because candidate genes responsible for susceptibility to AS
are mostly unknown and available data suggest the
possibility of a problem related with the NO pathway, this
study aimed to assess the association of common eNOS gene
polymorphisms with AS.
& METHODS
Sample size, patients and controls
Sample size was calculated using the results of previous
studies that investigated eNOS gene polymorphisms in
Turkish patients with inflammatory rheumatic diseases
based on a= 0.05 and a power of 80% (11,12). The minimum
minor allele frequencies required for this estimation for each
group were as follows: Exon 7 (G-894T), 96 subjects;
promoter (T-786C), 94 subjects; and intron 4 (variable
number of tandem repeat polymorphisms, VNTR), 58
subjects.
We included 194 unrelated AS patients diagnosed
according to the modified New York criteria (13). Patients
without a history of hypertension (current anti-hypertensive
treatment and/or observation of blood pressure levels
.140/90 mmHg), diabetes mellitus (participants who
reported having ever been told by a physician that they
have diabetes mellitus or who reported taking insulin or
pills to lower blood glucose levels) or coronary artery
disease (history of myocardial infarction, angina pectoris or
coronary artery angioplasty) were recruited consecutively
from the rheumatology outpatient clinics of the Dokuz Eylul
University and three training hospitals (Ataturk, Bozyaka
and Tepecik) located in Izmir city. A total of 113 healthy
controls subject undergoing the same exclusion criteria as
the patients and who did not have any first-degree relatives
with diagnoses of AS or related spondyloarthropathies were
recruited from the relatives of health professionals and
blood donors. Spinal mobility was assessed by the Bath
Ankylosing Spondylitis Metrology Index (BASMI) (14).
Patients were also evaluated with the Bath Ankylosing
Spondylitis Functional Index (BASFI) (15) and the Bath
Ankylosing Spondylitis Disease Activity Index (BASDAI)
(16). The Ministry of Health of Turkey Ethics Committee
approved the study, and all individuals provided informed
consent prior to blood collection in compliance with the
principles of the Declaration of Helsinki.
Genotyping
For all subjects, peripheral blood samples were collected
into sterile tubes with EDTA. Genomic DNA was extracted
from whole blood using standard proteinase K digestion and
the salt-chloroform method. The PCR-RFLP analysis method
was used to evaluate the association between three poly-
morphisms in the eNOS gene and AS. Three PCR primer sets
were used for amplification of each polymorphic region,
including the Glu298Asp (rs1799983, exon 7), 2786T.C
(rs2070744, promoter region) and 4b4a (intron 4, 27 bp repeat)
regions. The primers were designed using the Primer3
algorithm via the primer-BLAST interface on the NCBI
BLAST web site. PCR primer sequences, annealing
temperatures and product sizes were as follows: Glu298Asp:
(forward) 59-GTCACGGAGACCCAGCCAATG-39 and (reverse)
59-GCCCTTCTTGAGAGGCTCAGGGAT-39, 61.4 C˚, 325 bp; -
786T.C: (forward) 59-AGCTAGTGGCCTTTCTCCAGCCC-39
and (reverse) 59-CCCAGCCCCAATTTCCTGGAACC-39,
61.4 C˚, 335 bp; and VNTR repeat region: (forward) 59-GCCTT-
GGCTGGAGGAGGGGA-39 and (reverse) 59-TGGGGGAGA-
AGCAGCAGCCA-39, 57.1 C˚, 242 bp. For the Glu298Asp and
2786T.C regions, PCR products were digested using MboI
(Fermentas, Vilnius, Lithuania) and HpaII (New England
Biolab, Hitchin, UK) restriction endonuclease enzymes,
respectively. Restriction fragments were separated by electro-
phoresis on a gel composed of 3% agarose. For the Glu298Asp
region, the T allele resulted in 195 and 130 bp bands, while the
G allele resulted in single band of 225 bp. For the 2786T.C
region, the C allele resulted in 167, 46 and 122 bp bands, while
the T allele resulted in 122 and 213 bp bands. The 27 bp VNTR
repeat region in intron 4 was analyzed by direct electrophor-
esis on 3% agarose gel after PCR amplification. The 4b allele
amplicon size was 242 bp, whereas the 4a allele amplicon size
was 215 bp. HLA B27 analysis for the patient group was
performed using a commercially available SSP-typing kit
(Olerup; QIAGEN Vetriebs GmbH, Wien, Austria) according
to the manufacturer’s recommendations. SSP-typing results
were visualized using 2% agarose gel electrophoresis.
Statistical analysis
MedCalc software, version 12.3.0.0 (MedCAlc,
Mariakerke, Belgium), was used to estimate sample size.
The rest of the statistical analysis was performed on SPSS v.
16.0 software (SPSS Inc, Chicago, IL). Data are expressed as
the means¡ SDs for continuous variables or as percentages
of the total for categorical variables. Pearson x2 or Fisher’s
exact tests were used to assess intergroup significance, and a
Student’s t test was used to determine differences in means.
The distribution of the control genotypes was checked for
the Hardy–Weinberg equilibrium. The overall distributions
of alleles and genotypes for each polymorphism were
compared between cases and controls using x2 analyses.
Associations between alleles and genotypes and other
variables were examined by x2 tests. An analysis of
covariance (ANCOVA) was used to control for confounding
variables. A double-tailed p-value of , 0.05 was considered
statistically significant.
& RESULTS
There were 194 AS patients (139 male [M], 55 female [F];
41.5¡10.8 years) and 113 healthy controls (69 M, 44 F;
38.6¡11.1 years). Sex distributions were similar between the
patient and control groups (p = 0.07); however, age was
significantly lower in the control group compared with the
patients (p = 0.03). Disease duration for the patients was
14.9¡9.5 years. HLA-B27 was positive in 72% of patients.
The mean BASMI (0-10), BASFI (0-10) and BASDAI (0-10)
values were 2.8¡2.4, 3.2¡2.3 and 3.2¡2.5, respectively. The
clinical and demographical features of the patient and
control groups are given in Table 1.
All studied polymorphisms satisfied the Hardy-Weinberg
equilibrium in the controls (eNOS T-786C: X2(1) = 1.96,
p = 0.16; eNOS 4b4a VNTR: X2(1) = 2.74, p = 0.09; eNOS
Glu298Asp: X2(1) = 1.21, p = 0.27).
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Genotype distributions
The frequencies of the T/C polymorphisms at position -
786 in the promoter region (patients vs. controls) were as
follows: TT (46.3% vs. 34.8%), TC (46.3% vs. 53.6%) and CC
(7.4% vs. 11.6%) (p = 0.12). The frequencies of polymorph-
isms in exon 7 (Glu298Asp; patients vs. controls) were as
follows: GG (57.5% vs. 50.9%), GT (35.8% vs. 43.8%) and
TT (6.7% vs. 5.4%) (p = 0.36). The frequencies of 4b4a
VNTR (intron 4) polymorphisms (patients vs. controls)
were as follows: bb (71.7% vs. 65.2%), ba (26.7% vs. 33.9%)
and aa (1.6% vs. 0.9%) (p = 0.3). After controlling for age
and sex, the distributions of the genotypes (T-786C,
Glu298Asp and 4b4a VNTR) were still not significantly
different between the patients and controls (p = 0.06, 0.43
and 0.38, respectively).
Allelic distributions
eNOS T-786C (patients vs. controls) was distributed as T
(69.4% vs. 61.6%) and C (30.6% vs. 38.4%) (p = 0.07).
Glu298Asp (patients vs. controls) was distributed as G
(75.4% vs. 72.8%) and T (24.6% vs. 27.2%) (p = 0.5). 4b4a
VNTR (patients vs. controls) was distributed as b (85.1% vs.
82.1%) and a (14.9% vs. 17.9%) (p = 0.36). There were still no
significant differences between the groups regarding T-
786C, Glu298Asp and 4b4a VNTR alleles after controlling
for age and sex (p = 0.08, 0.44 and 0.48, respectively). A
summary of the allele and genotype frequencies of the three
investigated eNOS gene polymorphisms in AS patients and
healthy controls is given in Table 2.
Correlation analysis
The correlation analysis showed that eNOS gene poly-
morphism T-786C was not correlated with the variables of
disease duration, BASMI, BASFI, BASDAI or HLAB27
(p = 0.2, 0.1, 0.4, 0.4 and 0.8, respectively). These variables
were also not correlated with the Glu298Asp (p = 0.3, 0.3, 0.2,
0.4 and 0.6, respectively) or 4b4a VNTR (p = 0.9, 0.6, 0.4, 0.4
and 0.2, respectively) polymorphisms.
& DISCUSSION
In this study, we showed that the frequencies of common
eNOS gene polymorphisms were not different between AS
patients and controls. We also observed that these poly-
morphisms were not associated with disease duration,
activity, function, severity or HLAB27.
NO is a molecule that plays an important role in a variety
of physiologic functions, including the regulation of blood
vessel tone, inflammation, mitochondrial functions and
apoptosis (17). In mammals, NO can be generated by three
different isoforms of the enzyme NO synthase, including the
neuronal, inducible and endothelial forms (18). All three
NOS isozymes have regulatory functions in the cardiovas-
cular (CV) system (18). The most important isoform is
eNOS, which keeps blood vessels dilated, controls blood
pressure and has numerous other vasoprotective and anti-
atherosclerotic effects (18). Endothelium-derived NO
synthase is encoded by the eNOS gene on chromosome 7
(7). In recent years, several polymorphisms of the eNOS
gene and their associations with various diseases have been
Table 1 - Clinical and demographic characteristics of the patients and controls.
AS patients (n = 194) Healthy controls (n = 113) p-value
Age (years) 41.5¡10.8 38.6¡11.1 0.03
Sex, M/F 139/55 69/44 0.07
HLAB27 positivity, % 72
Disease duration (years) 14.9¡9.5
BASMI (0-10) 2.8¡2.4
BASFI (0-10) 3.2¡2.3
BASDAI (0-10) 3.2¡2.5
Continuous data are presented as the means ¡ standard deviations. BASMI = Bath Ankylosing Spondylitis Metrology Index, BASFI = Bath Ankylosing
Spondylitis Functional Index, BASDAI = Bath Ankylosing Spondylitis Disease Activity Index.
Table 2 - Allele and genotype frequencies of the eNOS gene polymorphisms in patients with AS and healthy controls.
Alleles % (n) Genotypes % (n)
eNOS -786 T C TT TC CC
Patients (n = 188) 69.4 (261) 30.6 (115) 46.3 (87) 46.3 (87) 7.4 (14)
Controls (n = 112) 61.6 (138) 38.4 (86) 34.8 (39) 53.6 (60) 11.6 (13)
p-value 0.07 0.12
eNOS 27 bp VNTR b a bb ba aa
Patients (n = 191) 85.1 (325) 14.9 (57) 71.7 (137) 26.7 (51) 1.6 (3)
Controls (n = 112) 82.1 (184) 17.9 (40) 65.2 (73) 33.9 (38) 0.9 (1)
p-value 0.36 0.3
eNOS+894 (Glu298Asp) G T GG GT TT
Patients (n = 193) 75.4 (291) 24.6 (95) 57.5 (111) 35.8 (69) 6.7 (13)
Controls (n = 112) 72.8 (163) 27.2 (61) 50.9 (57) 43.8 (49) 5.4 (6)
p-value 0.5 0.36
Note that no significant differences were found in the distributions of allele and genotype frequencies of the studied eNOS gene polymorphisms between
patients and controls.
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studied. In particular, a single nucleotide polymorphism in
the promoter region (T-786C), a 894G .T polymorphism
leading to amino acid substitution at position 298
(Glu298Asp, rs1799983) in exon 7, and the 4b4a polymorph-
ism (a VNTR) located in intron 4 of the eNOS have received
the most attention due to their functional relevance to eNOS
activity (19). It has been shown that the T-786C polymorph-
ism reduces eNOS gene promoter activity and affects eNOS
protein expression, while the Glu298Asp polymorphism
causes a structural change in the eNOS protein associated
with impaired eNOS activity (20,21). In addition, it has also
been shown that the 27bp-VNTR polymorphism reduces the
plasma concentration of NO (22). The dysregulation of
eNOS caused by these gene polymorphisms leads to
decreased NO production and is thought to contribute to
the pathogenesis of several diseases, including inflamma-
tory disorders. In this study, we investigated three common
eNOS gene polymorphisms (T-786C, Glu298Asp = G894T
and 4b4a VNTR) that have been shown to be associated with
eNOS activity. It has been reported that these polymorph-
isms are associated with CV risk factors and CV disease (7).
In the current study, to avoid the confounding effects of
these variables on our parameters, we excluded subjects
with hypertension, diabetes mellitus and CVD. We also
performed statistical adjustments for age and sex to
minimize the effects of demographics on our results.
Because of its relationship with inflammation, several
studies have investigated the association of eNOS gene
polymorphisms with inflammatory rheumatic diseases,
including rheumatoid arthritis, systemic lupus erythemato-
sus, systemic sclerosis and Behcet’s disease (11,12,17,23,24).
Some of these studies have yielded evidence of an
association of the eNOS polymorphisms with either the
pathogenesis of rheumatic diseases or extraarticular mani-
festations (12,17,23,24). It is well known that there is a strong
genetic basis for AS, and some genes, particularly HLAB27,
have already been implicated in disease pathogenesis. In
recent years, several other non-MHC genes, including genes
involved in intracellular antigen processing and cytokine
production (especially genes in the IL–17–IL–23 pathway),
have also been shown to be related to AS (1). However, it is
not known whether AS is associated with eNOS gene
polymorphisms.
In the current study, we investigated eNOS gene
polymorphisms in AS patients for the following reasons.
(1) Previous studies have reported an increased frequency
of impaired vascular relaxation (which is known to be
mediated by NO) (2-4,6) and higher levels of ADMA (8-10).
Although ADMA impairs post-NO production (unrelated to
eNOS polymorphisms), it is responsible for the decreased
NO activity (8-10). Based on these findings, we suggest that
the NO pathway may be impaired and that this might be
associated with genetic polymorphisms in the eNOS gene
(2). Some reports have revealed an association between
eNOS gene polymorphisms and inflammatory diseases
(11,12,17,23,24). Because the pathogenesis of the genes is
not fully understood in such inflammatory diseases, we
wondered whether there was a link between eNOS gene
polymorphisms and AS. We did not find any differences
between patients and controls regarding common eNOS
gene polymorphisms. We also did not find any relationship
between eNOS gene polymorphisms, HLAB27, disease
severity, function or activity.
We acknowledge that there were some limitations in our
study. (1) We did not study the surrogate markers of
atherosclerosis or biomarkers such as carotid intima-media
thickness, flow-mediated dilatation and ADMA in this
study. Upon consideration, the use of these parameters
may be more appropriate for drawing conclusions about
eNOS polymorphisms in AS. (2) The inclusion of AS
patients with CV risk factors may be more useful for
understanding the significance of these polymorphisms in
patients with or without CV conditions. In conclusion,
despite these limitations, the results presented in this study
do not provide support for a major role of common eNOS
polymorphisms in Turkish AS patients. Further replication
studies in different populations with larger numbers of
patients are needed to confirm our results.
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